메뉴 건너뛰기




Volumn 16, Issue 1, 2017, Pages

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: A subgroup analysis of the PROLOGUE study

(16)  Yamada, Hirotsugu a   Tanaka, Atsushi b   Kusunose, Kenya a   Amano, Rie a   Matsuhisa, Munehide c   Daida, Hiroyuki d   Ito, Masaaki e   Tsutsui, Hiroyuki f   Nanasato, Mamoru g   Kamiya, Haruo h   Bando, Yasuko K i   Odawara, Masato j   Yoshida, Hisako b   Murohara, Toyoaki i   Sata, Masataka a   Node, Koichi b  


Author keywords

Diastolic function; Echocardiography; NT proBNP; Sitagliptin; T2DM

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; HEMOGLOBIN A1C; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN;

EID: 85019079497     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0546-2     Document Type: Article
Times cited : (47)

References (45)
  • 1
    • 0016251063 scopus 로고
    • Role of diabetes in congestive heart failure: the Framingham study
    • Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29-34.
    • (1974) Am J Cardiol , vol.34 , Issue.1 , pp. 29-34
    • Kannel, W.B.1    Hjortland, M.2    Castelli, W.P.3
  • 2
    • 77953821528 scopus 로고    scopus 로고
    • Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al.: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
    • Emerging Risk Factors C. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al.: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
    • (2010) Lancet , vol.375 , Issue.9733 , pp. 2215-2222
  • 3
    • 84930079243 scopus 로고    scopus 로고
    • Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
    • Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385(9982):2107-17.
    • (2015) Lancet , vol.385 , Issue.9982 , pp. 2107-2117
    • Gilbert, R.E.1    Krum, H.2
  • 5
    • 44949172981 scopus 로고    scopus 로고
    • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
    • MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85.
    • (2008) Eur Heart J , vol.29 , Issue.11 , pp. 1377-1385
    • MacDonald, M.R.1    Petrie, M.C.2    Varyani, F.3    Ostergren, J.4    Michelson, E.L.5    Young, J.B.6    Solomon, S.D.7    Granger, C.B.8    Swedberg, K.9    Yusuf, S.10
  • 9
  • 10
    • 84988629139 scopus 로고    scopus 로고
    • Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes
    • Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19(1):43-53.
    • (2017) Eur J Heart Fail , vol.19 , Issue.1 , pp. 43-53
    • Fitchett, D.H.1    Udell, J.A.2    Inzucchi, S.E.3
  • 14
    • 84930085787 scopus 로고    scopus 로고
    • Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
    • Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76.
    • (2015) Lancet , vol.385 , Issue.9982 , pp. 2067-2076
    • Zannad, F.1    Cannon, C.P.2    Cushman, W.C.3    Bakris, G.L.4    Menon, V.5    Perez, A.T.6    Fleck, P.R.7    Mehta, C.R.8    Kupfer, S.9    Wilson, C.10
  • 15
  • 16
    • 84904007147 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants
    • Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-58.
    • (2014) Cardiovasc Ther , vol.32 , Issue.4 , pp. 147-158
    • Wu, S.1    Hopper, I.2    Skiba, M.3    Krum, H.4
  • 17
    • 84901188346 scopus 로고    scopus 로고
    • Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study
    • Oyama J, Ishizu T, Sato Y, Kodama K, Bando YK, Murohara T, Node K. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. Int J Cardiol. 2014;174(2):383-4.
    • (2014) Int J Cardiol , vol.174 , Issue.2 , pp. 383-384
    • Oyama, J.1    Ishizu, T.2    Sato, Y.3    Kodama, K.4    Bando, Y.K.5    Murohara, T.6    Node, K.7
  • 19
    • 29244432482 scopus 로고    scopus 로고
    • Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
    • Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440-63.
    • (2005) J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr , vol.18 , Issue.12 , pp. 1440-1463
    • Lang, R.M.1    Bierig, M.2    Devereux, R.B.3    Flachskampf, F.A.4    Foster, E.5    Pellikka, P.A.6    Picard, M.H.7    Roman, M.J.8    Seward, J.9    Shanewise, J.S.10
  • 21
    • 29244432482 scopus 로고    scopus 로고
    • Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
    • Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440-63.
    • (2005) J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr , vol.18 , Issue.12 , pp. 1440-1463
    • Lang, R.M.1    Bierig, M.2    Devereux, R.B.3    Flachskampf, F.A.4    Foster, E.5    Pellikka, P.A.6    Picard, M.H.7    Roman, M.J.8    Seward, J.9    Shanewise, J.S.10
  • 22
    • 84937227669 scopus 로고    scopus 로고
    • Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
    • 1727a-1727c
    • Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015; 36(27):1718-1727, 1727a-1727c.
    • (2015) Eur Heart J , vol.36 , Issue.27 , pp. 1718-1727
    • Seferovic, P.M.1    Paulus, W.J.2
  • 23
    • 65449125347 scopus 로고    scopus 로고
    • Changes in diastolic dysfunction in diabetes mellitus over time
    • From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009;103(10):1463-6.
    • (2009) Am J Cardiol , vol.103 , Issue.10 , pp. 1463-1466
    • From, A.M.1    Scott, C.G.2    Chen, H.H.3
  • 25
  • 26
    • 84962090232 scopus 로고    scopus 로고
    • Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial
    • Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39(3):455-64.
    • (2016) Diabetes Care , vol.39 , Issue.3 , pp. 455-464
    • Mita, T.1    Katakami, N.2    Shiraiwa, T.3    Yoshii, H.4    Onuma, T.5    Kuribayashi, N.6    Osonoi, T.7    Kaneto, H.8    Kosugi, K.9    Umayahara, Y.10
  • 27
    • 84962052181 scopus 로고    scopus 로고
    • Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)
    • Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139-48.
    • (2016) Diabetes Care , vol.39 , Issue.1 , pp. 139-148
    • Mita, T.1    Katakami, N.2    Yoshii, H.3    Onuma, T.4    Kaneto, H.5    Osonoi, T.6    Shiraiwa, T.7    Kosugi, K.8    Umayahara, Y.9    Yamamoto, T.10
  • 28
    • 84924331804 scopus 로고    scopus 로고
    • Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes
    • Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol. 2015;14:4.
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 4
    • Fontes-Carvalho, R.1    Ladeiras-Lopes, R.2    Bettencourt, P.3    Leite-Moreira, A.4    Azevedo, A.5
  • 29
    • 84896092380 scopus 로고    scopus 로고
    • Molecular mechanisms of diabetic cardiomyopathy
    • Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660-71.
    • (2014) Diabetologia , vol.57 , Issue.4 , pp. 660-671
    • Bugger, H.1    Abel, E.D.2
  • 33
    • 84867254999 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions
    • Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012;126(15):1838-51.
    • (2012) Circulation , vol.126 , Issue.15 , pp. 1838-1851
    • Shigeta, T.1    Aoyama, M.2    Bando, Y.K.3    Monji, A.4    Mitsui, T.5    Takatsu, M.6    Cheng, X.W.7    Okumura, T.8    Hirashiki, A.9    Nagata, K.10
  • 35
    • 77951168113 scopus 로고    scopus 로고
    • Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
    • Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59(4):1063-73.
    • (2010) Diabetes , vol.59 , Issue.4 , pp. 1063-1073
    • Sauve, M.1    Ban, K.2    Momen, M.A.3    Zhou, Y.Q.4    Henkelman, R.M.5    Husain, M.6    Drucker, D.J.7
  • 36
    • 77951812608 scopus 로고    scopus 로고
    • The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
    • Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454-65.
    • (2010) Am J Physiol Heart Circ Physiol , vol.298 , Issue.5 , pp. H1454-H1465
    • Ye, Y.1    Keyes, K.T.2    Zhang, C.3    Perez-Polo, J.R.4    Lin, Y.5    Birnbaum, Y.6
  • 37
    • 84865492997 scopus 로고    scopus 로고
    • Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
    • Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826-33.
    • (2012) Am J Cardiol , vol.110 , Issue.6 , pp. 826-833
    • Patil, H.R.1    Al Badarin, F.J.2    Al Shami, H.A.3    Bhatti, S.K.4    Lavie, C.J.5    Bell, D.S.6    O'Keefe, J.H.7
  • 38
    • 84900410339 scopus 로고    scopus 로고
    • Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease
    • McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7(2):274-81.
    • (2014) Circ Cardiovasc Imaging , vol.7 , Issue.2 , pp. 274-281
    • McCormick, L.M.1    Kydd, A.C.2    Read, P.A.3    Ring, L.S.4    Bond, S.J.5    Hoole, S.P.6    Dutka, D.P.7
  • 40
    • 84934910233 scopus 로고    scopus 로고
    • Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
    • Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 83
    • Oe, H.1    Nakamura, K.2    Kihara, H.3    Shimada, K.4    Fukuda, S.5    Takagi, T.6    Miyoshi, T.7    Hirata, K.8    Yoshikawa, J.9    Ito, H.10
  • 41
    • 84908394848 scopus 로고    scopus 로고
    • Rossi da Silva ME: left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study
    • Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL. Rossi da Silva ME: left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study. Diabetol Metab Syndr. 2014;6(1):103.
    • (2014) Diabetol Metab Syndr , vol.6 , Issue.1 , pp. 103
    • Nogueira, K.C.1    Furtado, M.2    Fukui, R.T.3    Correia, M.R.4    Santos, R.F.5    Andrade, J.L.6
  • 42
    • 84901462249 scopus 로고    scopus 로고
    • Cardiovascular actions of incretin-based therapies
    • Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788-803.
    • (2014) Circ Res , vol.114 , Issue.11 , pp. 1788-1803
    • Ussher, J.R.1    Drucker, D.J.2
  • 44
    • 84960100350 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
    • Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ (Clin Res ed). 2016;352:i610.
    • (2016) BMJ (Clin Res ed) , vol.352
    • Li, L.1    Li, S.2    Deng, K.3    Liu, J.4    Vandvik, P.O.5    Zhao, P.6    Zhang, L.7    Shen, J.8    Bala, M.M.9    Sohani, Z.N.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.